hotspot -WSS

hotspot

author：explore 2025-09-29 21:27:21 - browse：65491

Illustration of a teal cancer cell. -- health coverage from STAT — Illustration of a teal cancer cell. Adobe

Sana Biotechnology, a startup that just a couple of years ago raised over $1 billion off a grand plan to create a portfolio of powerful medicines, said Tuesday it would lay off nearly a third of its employees and de-prioritize one of its most ambitious programs as it looks to save money.

The layoffs are Sana’s second round of cuts in less than a year. It laid off 15% of staff last November after axing another program.

Tuesday’s move pushed back a program focused on turning a patient’s own immune cells into cancer-killing assassins or curing blood disorders such as sickle cell with just an IV infusion. Known as in vivo reprogramming, it was originally the company’s central focus and would have amounted to a monumental breakthrough.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Virginia high school admissions case could be legal follow
Next article： Hilary expected to bring catastrophic, life

hotspot

WSS

ADCs take center stage as promising cancer treatments

Cancer drug shortages' outsize impact on ovarian cancer patients

ActiGraph execs on goal of drug approvals with digital endpoints

New definition of a human embryo proposed amid rapid advances

Merck, Daiichi strike cancer drug pact worth up to $22 billion

Baltimore teen accused of firing into crowd during block party mass shooting

entertainment

hotspot

knowledge

How one medical school became remarkably diverse

STAT Readout: Friday, Oct. 20 biotech updates

Alkermes shareholders re

J&J lung cancer data amount to new salvo against AstraZeneca

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Living with Hashimoto's and celiac disease, and med school, too

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Why a market frenzy over new weight loss drugs defies logic

Medical records are filled with copy

ActiGraph execs on goal of drug approvals with digital endpoints

entertainment

Eye stem cell transplant could help restore vision in injured people

Readout Newsletter: AstraZeneca's CEO, Roivant's $5 billion deal

ADCs take center stage as promising cancer treatments

Results on Novartis prostate cancer therapy could expand its use

Clinical trials must include more disabled people

New details revealed about Purdue's marketing of OxyContin

hotspot

explore

focus

entertainment